Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525649 · ClinicalTrials.gov registry record · Phase 1
A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
A Phase 1 study, sponsored by NeuroPro Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06525649 is a Phase 1 study that has completed, run by NeuroPro Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT06525649, a Phase 1 study, has completed, sponsored by NeuroPro Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.
Interventions
- DRUG NPT 2042
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06525649
The ClinicalTrials.gov registry entry for NCT06525649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroPro Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NPT 2042 is the first listed.
NCT06525649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06525649 about?
NCT06525649 is a clinical study titled "A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042". A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.
What is the current status of trial NCT06525649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-08-21. Estimated completion is 2025-06-26.
What interventions are being tested in trial NCT06525649?
The interventions under investigation include: NPT 2042 (DRUG).
Who is sponsoring clinical trial NCT06525649?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.